Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06282081 · ClinicalTrials.gov registry record
Serum Neurofilament Light in Multiple Sclerosis
A clinical trial of Multiple Sclerosis and Relapsing Remitting Multiple Sclerosis, sponsored by Dent Neuroscience Research Center.
- Active
- Registry status
- 42
- Enrollment target
- 1
- Study location
NCT06282081: Active study of Multiple Sclerosis and Relapsing Remitting Multiple Sclerosis, sponsored by Dent Neuroscience Research Center.
NCT06282081 is a study of Multiple Sclerosis and Relapsing Remitting Multiple Sclerosis that is active but no longer recruiting, run by Dent Neuroscience Research Center. The registered enrollment target is 42 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06282081, a study of Multiple Sclerosis and Relapsing Remitting Multiple Sclerosis, is active but no longer recruiting, sponsored by Dent Neuroscience Research Center.
- ACTIVE NOT RECRUITING
- Registry status
- 42 participants
- Enrollment target
- 1
- Study location
Study Summary
This prospective cohort study is designed to characterize the utility of sNfL as a biomarker in clinical practice. This study also aims to understand how access to sNfL measures affects patient and clinician knowledge of their disease status and capture how this may have the potential to influence clinical decision-making. Level of disability, cognitive changes, fatigue, depression, and quality of life to detect clinical and subclinical worsening will be measured. While there is strong evidence in support of sNfL as a potential biomarker, literature regarding the application of sNfL in a real-world clinical practice setting is lacking. Understanding the utility of this test to clinicians and patients as a biomarker of MS disease activity is essential. Additionally, the optimum sampling frequency in clinical practice should be investigated to further elucidate its practicality. Given recent advances in the treatment of MS, there is increasing need for convenient and accessible measures of treatment efficacy.
Primary Outcome
This outcome is based on structured clinician questionnaires developed for this study. Prior to receiving patient sNfL results, clinicians will answer the question "My current clinical impression of this patient's disease status is (circle one): a. Stable, b. Suspected disease activity, c. Confirmed disease activity, d. At risk for relapse, e. Relapse, f. Other (please specify)." After receiving patient sNfL results, clinicians will answer the question "After reviewing this patient's sNfL result
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Serum Neurofilament Light
Study Locations (1)
New York
- Dent Neurologic Institute - Amherst
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2024-04-09 |
| Est. Completion | 2027-03-01 |
What the registry record for NCT06282081 still lists
NCT06282081 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (93% lower).
The record links to 2 conditions, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which Serum Neurofilament Light is the first listed.
NCT06282081 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06282081 about?
NCT06282081 is a clinical study titled "Serum Neurofilament Light in Multiple Sclerosis". This prospective cohort study is designed to characterize the utility of sNfL as a biomarker in clinical practice. This study also aims to understand how access to sNfL measures affects patient and clinician knowledge of their disease status and capture how this may have the potential to influence c...
What is the current status of trial NCT06282081?
This trial is currently active not recruiting. The enrollment target is 42 participants. The study started on 2024-04-09. Estimated completion is 2027-03-01.
What conditions does trial NCT06282081 study?
This clinical trial studies the following conditions: Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis.
What interventions are being tested in trial NCT06282081?
The interventions under investigation include: Serum Neurofilament Light (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06282081?
This trial is sponsored by Dent Neuroscience Research Center, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06282081 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06282081's enrollment target sits among peer trials
42 195th of 315 higher than 120 of 315 other Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
Prepare the Mind: Can Coaching in Goal-directed Behaviour Increase the Success of Cognitive Rehabilitation in People With MS?
RECRUITING · NA
-
Incremental Vestibulo-ocular Reflex Adaptation as a Novel Treatment for Dizziness in People With Multiple Sclerosis
RECRUITING · NA
-
Vancomycin Study in Multiple Sclerosis (MS)
RECRUITING · Phase 1
-
IConquerMS™ - a Patient-Powered Research Network for Multiple Sclerosis
RECRUITING
-
Prospective Investigation of Multiple Sclerosis in the Three Rivers Region
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI